Compositions and Methods for Producing Megakaryocytes
AssigneeStellular Bio, Inc.
InventorsJonathan Thon, Brad Dykstra
Life of this patent
Estimating the term…
Abstract
Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.
Claims24
-48. (canceled)
A method for cell production comprising:
- culturing pluripotent stem cells under continuous agitation such that the pluripotent stem cells form self-aggregating pluripotent cell spheroids;
- differentiating the self-aggregating pluripotent cell spheroids in a first culture medium into hemogenic endothelial cell spheroids;
- and
- differentiating the hemogenic endothelial cell spheroids in a second culture medium to produce megakaryocyte progenitors (preMKs), causing the hemogenic endothelial cell spheroids to release the preMKs into suspension while maintaining the hemogenic endothelial cell spheroids for subsequent production and release of the preMKs.
A method for cell production comprising:
- differentiating pluripotent stem cells in a first culture medium into hemogenic endothelial cells;
- and
- differentiating the hemogenic endothelial cells in a second culture medium into preMKs,
- wherein each of the differentiating the pluripotent cells and the differentiating the hemogenic endothelial cells is carried out in suspension to enable the pluripotent cells to self-aggregate into hemogenic endothelial cell spheroids and the hemogenic endothelial cells in the hemogenic endothelial cell spheroids to differentiate into preMKs, causing the hemogenic endothelial cell spheroids to release the preMKs into suspension while maintaining the hemogenic endothelial cell spheroids for subsequent production and release of the preMKs.
A method of treating or ameliorating a condition in a subject in need of such treatment, the method comprising administering to the subject a composition comprising megakaryocyte progenitors (preMKs), megakaryocytes (MKs), or lysates thereof in an effective amount to treat or ameliorate the condition in the subject compared to a patient not treated with the composition comprising the preMKs or lysates thereof.
Dependencies are inferred from the claim text.